Navigation Links
Januvia Lawsuits Being Investigated By Bernstein Liebhard LLP on Behalf of Januvia Patients Who Were Diagnosed with Pancreatic Cancer, Pancreatitis and Thyroid Cancer
Date:8/11/2013

New York, New York (PRWEB) August 11, 2013

Bernstein Liebhard LLP is investigating Januvia lawsuits (http://www.thejanuvialawsuit.com/) on behalf of Type 2 diabetics who took Januvia and were later diagnosed with pancreatic cancer, pancreatitis or thyroid cancer. According to court documents, a growing number of Januvia lawsuits have been filed against Merck & Co. that accuse the drug maker of failing to warn doctors and patients of an association between the use of Januvia and pancreatic cancer, as well as pancreatitis. The U.S. Judicial Panel on Multidistrict Litigation (JPML) is expected to make a decision soon regarding the establishment of a multidistrict litigation for all federal lawsuits involving allegations that Januvia and similar diabetes medications can increase risks for pancreatic cancer, pancreatitis and thyroid cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

“We have heard from a number of Januvia users who have been diagnosed with pancreatic cancer, pancreatitis and thyroid cancer. The body of evidence pointing to a possible connection between the use of drugs like Januvia and an increased risk for these diseases continues to grow,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Januvia lawsuit consultations to anyone who may have been harmed after taking Januvia or a similar drug.

Januvia and Pancreatic Cancer
Januvia belongs to a class of type 2 diabetes drugs known as incretin mimetics, which help regulate blood sugar by stimulating insulin production by the pancreas. In 2009, a caution regarding a potential Januvia pancreatitis risk was added to the drug’s label after the U.S. Food & Drug Administration (FDA) became aware of 88 post-marketing cases of acute pancreatitis in patients taking Januvia.* In 2011, a study published in Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis and pancreatic cancer, while two cases of thyroid cancer were also reported in the patients who took Januvia.**

The FDA announced in March that it was investigating incretin mimetics after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas. While the agency has not yet been able to confirm a conclusive link between the use of such drugs and pancreatic cancer, it has said its “review is ongoing as pancreatitis and pancreatic cancer data are being collected.”*** Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.****

Patients who have developed pancreatic cancer, thyroid cancer or pancreatitis that may be related to the use of Januvia could be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn More about the possible link between Januvia and pancreatic cancer by visiting Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**http://www.gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***pharmalive.com/fda-decides-no-risk-of-pancreatic-cancer-with-diabetes-drugs, Pharmalot, July 31, 2013
****bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thejanuvialawsuit.com/

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb11015829.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Januvia Pancreatic Cancer Lawsuit: Bernstein Liebhard LLP Comments on Growing Litigation Surrounding Januvia
2. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
3. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
4. New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
5. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
6. Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics
7. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
8. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
9. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
10. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
11. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Dairy Products, Inc. in an upcoming episode, airing third quarter 2016 via Discovery ... churning cream into butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies product ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County ... Dr. Daniel A. Potter -- are proud of the recent release of their 2014 ... April, SART published the latest verified data for 375 U.S. member clinics. ...
(Date:4/29/2016)... ... 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend and sponsor ... the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event is the ... protein ingredients. , At the seminar, IDF™ will offer samples of its Savory ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase ... period, and an increase of 1.2% on an adjusted pro ... first quarter were $0.52 reported, a decrease of 47.5% from ... 29.9% over the prior year period , The Company ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ...
(Date:4/28/2016)... April 28, 2016  ValGenesis, Inc., the ... Solutions (VLMS) today announced that a prominent ... sufferers of chronic kidney failure has selected ... their corporate validation process. The global medical ... solution to manage their validation processes electronically. ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
Breaking Medicine Technology: